Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab Monotherapy in Moderate-to-Severe Atopic Dermatitis (SOLO 1)
NCT02277743Phase 3Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Oct 2014
- Primary completion
- Nov 2015
- Modality
- Monoclonal Antibodies
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial of dupilumab in atopic dermatitis (AD) (3 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoint: Proportion of patients with Investigator's Global Assessment (IGA) score of 0 or 1 and reduction from baseline of >= 2 points at 16 weeks. Started Oct 2014; status: completed.
02
Drugs
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT02277743.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02277743.